Article

Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma.

Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
International Journal of Cancer (Impact Factor: 5.01). 06/2009; 124(11):2616-20. DOI: 10.1002/ijc.24245
Source: PubMed

ABSTRACT Allergy/atopy has been suggested to protect against non-Hodgkin lymphoma (NHL) and specific IgE levels are decreased in patients with NHL. We speculated that all immunoglobulin subclass levels might be downregulated in NHL and examined levels of IgM, IgD, IgA, IgE, IgG and IgG(4) in 200 NHL patients and 200 age- and sex-matched controls. Patients with B-cell NHL of many types had consistently lower median immunoglobulin subclass levels than controls. In every subclass except IgD, about 10-15% of B-cell NHL patients had absolute levels below the 2.5 percentile of controls. Subclass levels correlated with each other and many patients had more than one significantly low level. Levels were lowest for IgG(4) and IgE. Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma had especially low total IgE levels. In other B-cell NHL types, total IgE levels were decreased to a similar extent as other immunoglobulin subclasses. In conclusion, low IgE levels are only part of a more generalized loss of immunoglobulins of all subtypes in a wide variety of B-cell NHL types. Low immunoglobulin levels appear to be a consequence of B-cell NHL presence, and we speculate about molecular mechanisms that could reduce all immunoglobulin subclasses in B-cell NHL.

Download full-text

Full-text

Available from: Michael Christiansen, Oct 13, 2014
0 Followers
 · 
108 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypogammaglobulinemia is common in Waldenström's macroglobulinemia. The etiology of this finding remains unclear, but it has been speculated to be based on tumor-induced suppression of the 'uninvolved' immunoglobulin production We evaluated the incidence of IgA and IgG hypogammaglobulinemia in 207 untreated patients with Waldenström's macroglobulinemia and investigated the associated clinicopathological findings and impact of therapy. We also sequenced eight genes (AICDA, BTK, CD40, CD154, NEMO, TACI, SH2D1A, UNG) implicated in immunoglobulin deficiency in 19 Waldenström's macroglobulinemia patients with IgA and/or IgG hypogammaglobulinemia. At baseline 63.3%, 58.0% and 49.3% of the 207 patients had abnormally low serum levels of IgA, IgG, or both. No association between IgA and IgG hypogammaglobulinemia and disease burden, serum IgM levels, beta(2)-microglobulin, International Prognostic Scoring System score, or incidence of recurrent infections was observed, although the presence of adenopathy and/or splenomegaly was associated with a lower incidence of hypogammaglobulinemia. Lower IgA and IgG levels were associated with disease progression in patients managed with a 'watch and wait' strategy. IgA and/or IgG levels remained abnormally low despite response to treatment, including complete remissions. A missense mutation in the highly conserved catalytic site of UNG was observed in a patient with hypogammaglobulinemia, warranting further study of this pathway in Waldenström's macroglobulinemia. IgA and IgG hypogammaglobulinemia is common in Waldenström's macroglobulinemia and persists despite therapeutic intervention and response. IgA and IgG hypogammaglobulinemia does not predict the risk of recurrent infections in patients with Waldenström's macroglobulinemia, although lower levels of serum IgA and IgG are associated with disease progression in Waldenström's macroglobulinemia patients being managed with a 'watch and wait' strategy.
    Haematologica 11/2009; 95(3):470-5. DOI:10.3324/haematol.2009.010348 · 5.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lymphoma, although rare, is the most common haematopoietic neoplasm encountered in horses and can occur at any age, with horses 4–10 years more commonly affected. Lymphoma can be classified into multicentric, alimentary, mediastinal, cutaneous and solitary. Clinical signs are typically nonspecific until the disease has progressed to end-stage at which time clinical signs reflect function of organ(s) involved. Horses with the cutaneous form of lymphoma typically present with multifocal skin lesions and no other clinical signs. Like the nonspecific clinical signs of lymphoma, results of complete blood count (CBC) and serum biochemistries are not often helpful with diagnosis, but lymphoma should be considered if anaemia, hyperfibrinogenaemia, hyperproteinaemia and hypoalbuminaemia are observed without a clear indication of infectious disease. Identification of neoplastic lymphocytes during cytological examination of a body cavity effusion can confirm the presence of lymphoma. Typically, ante mortem confirmation of lymphoma is made through histopathological examination of a biopsy or cytological examination of a fine needle aspirate of a suspected lesion. Observation of compression or destruction of normal tissue architecture by invading neoplastic cells during histological examination is indicative of lymphoma. Additional diagnostics that may improve our knowledge of equine lymphoma include detection of hormone receptors, immunophenotyping, and immunohistochemical analysis for tumour proliferation rates. Prognosis of horses with lymphoma depends on the form of lymphoma and stage at which the horse is presented but death is the common outcome of this disease. Current treatment options are surgical excision, radiation or administration of chemotherapeutic drugs. Treatment of horses with lymphoma can result in palliation and occasional resolution of this disease. Equine oncology is in its infancy, but through further documentation of horses with lymphoma and their response to therapy, a clearer understanding of the disease process and effective treatment of this neoplasm can be developed.
    03/2011; 23(4):205 - 213. DOI:10.1111/j.2042-3292.2010.00200.x
  • [Show abstract] [Hide abstract]
    ABSTRACT: The nexus of chemotherapeutic intervention and the immunomodulation of IgE-related phenomena are not well understood. The relationship bears importance in better understanding the causal and/or resultant effects of one on the other and their collective role in the management and sequelae of the cancer patient. This review discusses the relationship of chemotherapy on immunoglobulins with a focus on IgE and other related biological processes including hypersensitivity reactions and proposes models toward effective management of the cancer patient in this regard.
    Cancer Immunology and Immunotherapy 12/2011; 61(9):1585-90. DOI:10.1007/s00262-011-1170-8 · 3.94 Impact Factor